New diagnostic devices in heart failure

Current Opinion in Cardiology

Volumn 25, Issue 3, 2010, Pages 262-267

  Schlendorf, Kelly H ^a   Russell, Stuart D ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Heart failure; Implantable diagnostic devices; Intrathoracic impedance

Indexed keywords

CLINICAL TRIAL; DEVICE; ELECTRODIAGNOSIS; HEALTH CARE SYSTEM; HEART FAILURE; HEART HEMODYNAMICS; HEART LEFT ATRIUM PRESSURE; HEART RATE; HEART RHYTHM; HUMAN; LUNG CONGESTION; LUNG PRESSURE; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PREDICTION; PRESSURE MEASUREMENT; PRIORITY JOURNAL; PULMONARY ARTERY CATHETER; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; UNITED STATES;

CARDIOGRAPHY, IMPEDANCE; ELECTRIC IMPEDANCE; HEART FAILURE; HEART FUNCTION TESTS; HEMODYNAMICS; HUMANS; MONITORING, AMBULATORY; PRESSURE; PROSTHESES AND IMPLANTS; TRANSDUCERS, PRESSURE;

EID: 77952238770     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/HCO.0b013e3283387962     Document Type: Review

References (26)

1. Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke statistics 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009; 119: e21-e181.
2. Kimmelstiel C, Levine D, Perry K, et al. Randomized, controlled evaluation of short-and long-term benefits of heart failure disease management within a diverse provider network: the SPAN-CHF trial. Circulation 2004;110:1450-1455.
3. Pazin-Filho A, Peitz P, Pianta T, et al. Heart failure disease management program experience in 4, 545 heart failure admissions to a community hospital. Am Heart J 2009;158:459-466.
4. Gregory D, Kimmelstiel C, Perry K, et al. Hospital cost effect of a heart failure disease management program: the specialized primary and networked care in heart failure (SPAN-CHF) trial. Am Heart J 2006;151:1013-1019.
5. Kasper EK, Gerstenblith G, Hefter G, et al. A randomized trial of the efficacy of multidisciplinary care in heart failure outpatients at high risk of hospital readmission. J Am Coll Cardiol 2002;39:471-480.
6. Binanay C, Califf RM, Hasselblad V, et al. Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. JAMA 2005;294:1625-1633.
7. Bourge RC, Abraham WT, Adamson PB, et al. Randomized controlled trial of an implantable continuous hemodynamic monitor in patients with advanced heart failure. The COMPASS-HF study. J Am Coll Cardiol 2008;51:1073-1079. To date, this is the only published randomized, controlled trial that evaluates the utility of an implantable pressure-sensing monitor to reduce clinical heart failure events.
8. Hoppe UC, Vanderheyden M, Sievert H, et al. Chronic monitoring of pulmonary artery pressure in patients with severe heartfailure: multicentre experience of the monitoring Pulmonary Artery Pressure by Implantable device Responding to Ultrasonic Signal (PAPIRUS) II study. Heart 2009;95:1091-1097. This article describes the results of a safety and feasibility study evaluating the Impressure pressure-monitoring system in heart failure patients.
9. Ritzema J, Melton IC, Richards M, et al. Direct left atrial pressure monitoring in ambulatory heart failure patients: initial experience with a new permanent implantable device. Circulation 2007;116:2952-2959.
10. Yu C, Wang L, Chau E, et al. Intrathoracic impedance monitoring in patients with heart failure: correlation with fluid status and feasibility of early warning preceding hospitalization. Circulation 2005;112:841-848.
11. Abraham WT. Superior performance of intrathoracic impedance-derived fluid index versus daily weight monitoring in heart failure patients: results of the Fluid Accumulation Status Trial (FAST). Heart Failure Society of America 2009 Scientific Meeting; September 14, 2009; Boston, MA. Late Breaking Clinical Trials I. This presentation at the Heart Failure Society of America outlines results of one of the first prospective trials to explore the ability of implantable impedance monitors to predict heart failure events.
12. Magalski A, Adamson P, Gadler F, et al. Continuous ambulatory right heart pressure measurements with an implantable hemodynamic monitor: a multicenter, 12-month follow-up study of patients with chronic heart failure. J Cardiac Fail 2002;8:63-70.
13. Steinhaus D, Reynolds DW, Gadler F. Implant experience with implantable hemodynamic monitor for the management of symptomatic heart failure. Pacing Clin Electrophysiol 2005;28:747-753.
14. Adamson PB, Conti JB, Smith AL, et al. Reducing events in patients with chronic heart failure (REDUCEhf) study design: continuous hemodynamic monitoring with an implantable defibrillator. Clin Cardiol 2007;30:567-575.
15. Verdejo HE, Castro PF, Concepcion R, et al. Comparison of aradiofrequencybased wireless pressure sensor to Swan-Ganz catheter and echocardiography for ambulatory assessment of pulmonary artery pressure in heartfailure. J Am Coll Cardiol 2007;50:2375-2382.
16. Wang L, Lahtinen S, Lentz L, et al. Feasibility of using an implantable system to measure thoracic congestion in an ambulatory chronic heart failure canine model. Pacing Clin Electrophysiol 2005;28:404-411.
17. Small RS, Wickemeyer W, Germany R, et al. Changes in intrathoracic impedance are associated with subsequent risk of hospitalizations for acute decompensated heart failure: clinical utility of implanted device monitoring without patient alert. J Cardiac Fail 2009;15:475-481. This retrospective cohort study in patients whose CRT devices had impedancemonitoring capabilities shed light on the association between changes in impedance and heart failure hospitalization.
18. Wang L. Fundamentals of intrathoracic impedance monitoring in heartfailure. Am J Cardiol 2007; 99 (Suppl) : 3G-10G.
19. Cowie MR, Conraads V, Tavazzi L, et al. Rationale and design of a prospective trial to assess the sensitivity and positive predictive value of implantable intrathoracic impedance monitoring in the prediction of heart failure hospitalizations: The SENSE-HF study. J Cardiac Fail 2009;15:394-400.
20. Braunschweig F, Ford I, Conraads V, et al. Can monitoring of intrathoracic impedance reduce morbidity and mortality in patients with chronic heart failure? Rationale and design of the Diagnostic Outcome Trial in Heart Failure (DOT-HF). Eur J Heart Fail 2008;10:907-916.
21. Landolina M, Gasparini M, Lunati M, et al. Heart rate variability monitored by the implanted device predicts response to CRT and long-term clinical outcome in patients with advanced heartfailure. Eur J Heart Fail 2008;10:1073-1079.
22. Pozzoli M, Cioffi G, Traversi E, et al. Predictors of primary atrial fibrillation and concomitant clinical and hemodynamic changes in patients with chronic heart failure: a prospective study in 344 patients with baseline sinus rhythm. J Am Coll Cardiol 1998;32:197-204.
23. Mathew J, Hunsberger S, Fleg J, et al. Incidence, predictive factors, and prognostic significance of supraventricular tachyarrhythmias in congestive heart failure. Chest 2000;118:914-922.
24. Dries DL, Exner DV, Gersh BJ, et al. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trails. Studies of left ventricular dysfunction. J Am Coll Cardiol 1998;32:695-703.
25. Adamson PB, Smith A, Abraham WT, et al. Continuous autonomic assessment in patients with symptomatic heart failure: prognostic value of heart rate variability measured by an implanted cardiac resynchronization device. Circulation 2004;110:2389-2394.
26. Whellan DJ, O'Connor CM, Ousdigian KT, et al. Rationale, design, and baseline characteristics of a program to assess and review trending information and evaluate correlation to symptoms in patients with heart failure (PARTNERS HF). Am Heart J 2008;156:833-839.